JP2000507544A5 - - Google Patents

Download PDF

Info

Publication number
JP2000507544A5
JP2000507544A5 JP1997534520A JP53452097A JP2000507544A5 JP 2000507544 A5 JP2000507544 A5 JP 2000507544A5 JP 1997534520 A JP1997534520 A JP 1997534520A JP 53452097 A JP53452097 A JP 53452097A JP 2000507544 A5 JP2000507544 A5 JP 2000507544A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997534520A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000507544A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/004699 external-priority patent/WO1997035584A1/en
Publication of JP2000507544A publication Critical patent/JP2000507544A/ja
Publication of JP2000507544A5 publication Critical patent/JP2000507544A5/ja
Ceased legal-status Critical Current

Links

JP9534520A 1996-03-25 1997-03-24 痛みの治療方法 Ceased JP2000507544A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1415296P 1996-03-25 1996-03-25
US60/014,152 1996-03-25
PCT/US1997/004699 WO1997035584A1 (en) 1996-03-25 1997-03-24 Method for treating pain

Publications (2)

Publication Number Publication Date
JP2000507544A JP2000507544A (ja) 2000-06-20
JP2000507544A5 true JP2000507544A5 (enExample) 2004-12-02

Family

ID=21763836

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9534520A Ceased JP2000507544A (ja) 1996-03-25 1997-03-24 痛みの治療方法

Country Status (6)

Country Link
US (2) US6444665B1 (enExample)
EP (1) EP0906104A4 (enExample)
JP (1) JP2000507544A (enExample)
AU (1) AU2587297A (enExample)
CA (1) CA2250042A1 (enExample)
WO (1) WO1997035584A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2587297A (en) * 1996-03-25 1997-10-17 Eli Lilly And Company Method for treating pain
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
ES2151828B1 (es) * 1998-07-10 2001-08-16 Esteve Labor Dr Empleo de derivados de tetrahidropiridinas (ohidroxi-piperidinas)-b utilazoles en la elaboracion de un medicamento para el tratamiento del dolor.
EP1135121B1 (en) * 1998-11-13 2003-03-12 Eli Lilly And Company Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
DE19924929C2 (de) * 1999-05-31 2001-05-31 Elegene Gmbh Neues Verfahren zur Untersuchung der Eignung eines Materials als Pharmakon
EA200801806A1 (ru) 1999-07-01 2008-12-30 Фармация Энд Апджон Компани Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
WO2002060870A2 (en) * 2000-11-17 2002-08-08 Adolor Corporation Delta agonist analgesics
DE10112798A1 (de) * 2001-03-16 2002-10-02 Elegene Gmbh Vorrichtung und Verfahren zur automatischen Erzeugung einer Wärmevermeidungsreaktion von Nematoden oder ähnlichen Lebewesen
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
WO2003022261A1 (en) 2001-09-13 2003-03-20 Miller Kenneth E Method of alleviating pain
US6635675B2 (en) * 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
MXPA04007752A (es) * 2002-02-08 2005-06-17 Abbott Lab Terapia de combinacion para tratamiento de esquizofrenia.
US20050096395A1 (en) * 2002-02-12 2005-05-05 Rao Srinivas G. Methods of treating attention deficit/hyperactivity disorder (adhd)
ES2334991T3 (es) * 2002-03-26 2010-03-18 Teva Pharmaceutical Industries Ltd. Microparticulas de farmaco.
JP2005523334A (ja) * 2002-04-24 2005-08-04 サイプレス バイオサイエンス, インコーポレイテッド ストレス関連障害を含む機能的身体障害の予防および処置
AU2003227521A1 (en) * 2002-05-30 2003-12-19 Neurosearch A/S Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
AU2003284005B2 (en) * 2002-10-03 2009-12-17 Forest Laboratories Holdings Limited Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
AU2003295823B2 (en) * 2002-11-26 2009-11-05 Alexza Pharmaceuticals, Inc. Treatment of headache with antipsychotics delivered by inhalation
DE60325888D1 (de) 2002-11-26 2009-03-05 Alexza Pharmaceuticals Inc Verwendung von loxapine für die herstellung eines mittels zur behandlung von schmerz
RU2356554C2 (ru) 2002-12-27 2009-05-27 Оцука Фармасьютикал Ко., Лтд. Производные карбостирила и ингибиторы обратного захвата серотонина для лечения эмоциональных расстройств
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
US20040234914A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Percussively ignited or electrically ingnited self-contained heating unit and drug-supply unit employing same
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
EP1626721B1 (en) * 2003-05-23 2016-12-07 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and mood stabilizers for treating mood disorders
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
EP1715921B1 (en) * 2003-09-25 2013-04-24 Abraxis BioScience, Inc. Tetrahydroindolone derivatives for treatment of neurological conditions
US20050107439A1 (en) * 2003-11-10 2005-05-19 Helton David R. Composition and method for treating emesis
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EP1781360A1 (en) 2004-08-12 2007-05-09 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
EA200702558A1 (ru) 2005-05-20 2008-06-30 Янссен Фармацевтика Н. В. Способ получения производных сульфамида
UA97349C2 (uk) * 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
EP1795609A1 (en) 2005-12-06 2007-06-13 Sanofi-Aventis Deutschland GmbH Method for the diagnosis and treatment of cardiovascular diseases
US8551986B2 (en) * 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
EP2026790A2 (en) 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US8198305B2 (en) * 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
WO2009062134A1 (en) * 2007-11-09 2009-05-14 Cenomed Biosciences, Llc Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
NZ590682A (en) 2008-06-23 2012-09-28 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8697735B2 (en) 2008-07-25 2014-04-15 Bionevia Pharmaceuticals, Inc. Solid forms of epalrestat
AU2009288037B2 (en) 2008-09-06 2014-08-14 Bionevia Pharmaceuticals, Inc. Novel choline cocrystal of epalrestat
EA027136B1 (ru) * 2012-07-02 2017-06-30 Пнб Веспер Лайф Сайенс Пвт Лимитед Новые лиганды холецистокининовых рецепторов
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
ES2922501T3 (es) 2013-12-24 2022-09-15 Univ Virginia Commonwealth Uso de sulfatos de colesterol oxigenados (OCS) para el tratamiento de disfunción renal
EP3468540A4 (en) * 2016-06-13 2020-03-18 Board Of Regents Of the University Of Texas System PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2019152873A1 (en) 2018-02-02 2019-08-08 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
JP2022529476A (ja) 2019-04-17 2022-06-22 コンパス パスファインダー リミテッド 不安障害、頭痛障害、及び摂食障害をサイロシビンで治療するための方法
US12389955B2 (en) * 2021-10-22 2025-08-19 Nike, Inc. Garment adjusting system
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
GB1247067A (en) * 1968-02-16 1971-09-22 Fujisawa Pharmaceutical Co Tricyclic enol ether compounds and the preparation thereof
US3704345A (en) * 1971-03-19 1972-11-28 Bell Telephone Labor Inc Conversion of printed text into synthetic speech
DE2918778A1 (de) * 1979-05-10 1980-11-20 Basf Ag 6-substituierte 11-alkylen-morphantridine
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US5238945A (en) 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5045539A (en) * 1989-07-10 1991-09-03 Hoechst-Roussel Pharmaceuticals Inc. 1H-indolo[3,2-c]quinoline-derivatives, compositions containing same, useful for treating pain, psychosis or convulsions
DE69025943T2 (de) * 1989-08-21 1996-09-19 Beth Israel Hospital Verwendung von Spiperone-derivate zur Immunosuppression
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
DK203990D0 (da) * 1990-08-24 1990-08-24 Novo Nordisk As Piperazinylderivater
US5605897A (en) 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
US5229832A (en) 1991-07-08 1993-07-20 Industrial Quality, Inc. Optical ultrasonic material characterization apparatus and method
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
WO1995013814A1 (en) * 1993-11-19 1995-05-26 Janssen Pharmaceutica N.V. Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
NZ292429A (en) * 1994-09-02 2000-01-28 Univ Virginia Commonwealth Combination of non-narcotic analgesic and nmda receptor antagonist for alleviating pain
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
GB9604465D0 (en) * 1996-03-01 1996-05-01 Smithkline Beecham Plc Novel method
AU2587297A (en) * 1996-03-25 1997-10-17 Eli Lilly And Company Method for treating pain
EA000976B1 (ru) 1996-03-25 2000-08-28 Эли Лилли Энд Компани Композиция для снятия боли и способ снятия боли

Similar Documents

Publication Publication Date Title
JP2001503254A5 (enExample)
JP2000504599A5 (enExample)
JP2000501771A5 (enExample)
JP2000501599A5 (enExample)
JP2000501018A5 (enExample)
JP2000500076A5 (enExample)
JP2001501312A5 (enExample)
JP2000501324A5 (enExample)
JP2000500055A5 (enExample)
JP2000500026A5 (enExample)
JP2000501338A5 (enExample)
JP2001503812A5 (enExample)
JP2000500874A5 (enExample)
JP2000507439A5 (enExample)
JP2000505245A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2000507828A5 (enExample)
JP2000501744A5 (enExample)
JP2000501229A5 (enExample)
JP2000513979A5 (enExample)
JP2000500857A5 (enExample)
JP2000502714A5 (enExample)